Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [31] Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
    Roeker, Lindsey E.
    DerSarkissian, Maral
    Ryan, Kellie
    Chen, Yan
    Duh, Mei Sheng
    Wahlstrom, Svea K.
    Hakre, Shweta
    Yu, Louise
    Guo, Helen
    Mato, Anthony R.
    BLOOD ADVANCES, 2023, 7 (16) : 4291 - 4301
  • [32] Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine plus rituximab
    Irwin, Debra
    Wilson, Kathleen
    Thompson, Stephen
    Choudhry, Azhar
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 623 - 628
  • [33] Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)
    Mato, Anthony R.
    Ravelo, Arliene
    MyTo, Tu
    Schuldt, Robert
    Biondo, Juliana M. L.
    BLOOD, 2021, 138
  • [34] Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience
    Yang, Shenmiao
    Feng, Ru
    Guo, Xutao
    Li, Zhenling
    Ju, Qianqian
    Dong, Yujun
    Wang, Bingjie
    Zhao, Yu
    Wang, Liang
    Sun, Wanling
    Fang, Fang
    Wang, Liru
    Su, Liping
    Huang, Xiaojun
    BLOOD, 2024, 144 : 7819 - 7820
  • [35] Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study
    Huntington, Scott F.
    De Nigris, Enrico
    Puckett, Justin
    Kamal-Bahl, Sachin
    Farooqui, Mohammed Z. H.
    Ryland, Katherine Elizabeth
    Sarpong, Eric
    Yang, Xiaoqin
    Doshi, Jalpa
    BLOOD, 2022, 140 : 7939 - 7940
  • [36] Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
    Ghosh, Nilanjan
    Sharman, Jeff P.
    Barrientos, Jacqueline C.
    Brander, Danielle
    Gutierrez, Meghan
    Wu, Linda
    Qureshi, Zaina P.
    Upasani, Sandhya
    Naganuma, Maoko
    Mato, Anthony R.
    BLOOD, 2022, 140 : 7047 - 7049
  • [37] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [38] Combination of ibrutinib and venetoclax in first-line treatment of chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (01): : 12 - 13
  • [39] Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line
    Lu Xiaoxiao
    Bruno, Emond
    Laura, Morrison
    Frederic, Kinkead Frederic
    Patrick, Lefebvre
    Helene, Marie-Lafeuille
    Wasiulla, Khan
    Wu Linda
    Zaina, P. Qureshi Zaina P.
    Ryan, Jacobs
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S26 - S26
  • [40] Real-world time to discontinuation of first-line venetoclax plus obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, : 1227 - 1235
12345